Last reviewed · How we verify
Therapeutic dose anticoagulation
Direct Factor Xa inhibition prevents the coagulation cascade.
Direct Factor Xa inhibition prevents the coagulation cascade. Used for Prevention of stroke and systemic embolism in non-valvular atrial fibrillation, Treatment of deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Therapeutic dose anticoagulation |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is achieved by binding to Factor Xa, thereby preventing the conversion of prothrombin to thrombin and subsequent clot formation. This results in a reduction in the risk of thromboembolic events.
Approved indications
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
- Treatment of deep vein thrombosis and pulmonary embolism
Common side effects
- Major bleeding
- Gastrointestinal bleeding
- Hemorrhage
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Effect of iNO in Patients With Submassive and Massive PE (PHASE2)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Therapeutic dose anticoagulation CI brief — competitive landscape report
- Therapeutic dose anticoagulation updates RSS · CI watch RSS
- UMC Utrecht portfolio CI